查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1178161

缺血性中風的全球市場:市場規模 - 各診斷，各藥物類別，各手術，各終端用戶，各地區展望，競爭策略，各市場區隔預測(～2032年)

Ischemic Stroke Market Size- By Diagnosis, By Drug Class, By Surgery, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 248 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球缺血性中風的市場規模，預計至2032年達到135億4,000萬美元，以4.24％的年複合成長率成長。

由於健康意識的高漲，糖尿病患者增加，香煙使用數量增加，人口的高齡化等要素，牽引市場。缺血性中風的檢測和治療方法相關新開發技術的發展，對市場成長也有所貢獻。

本報告提供全球缺血性中風市場相關調查，市場動態，市場變數與展望，各診斷、藥物類別、手術、終端用戶、地區的市場分析，企業簡介等相關資訊。

目錄

第1章 簡介

  • 調查範圍
  • 市場區隔分析

第2章 調查手法

  • 調查資料來源
  • 市場規模的估計
  • 資料的三角測量

第3章 摘要整理

第4章 市場動態

  • 促進因素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • 全球缺血性中風市場上COVID-19的影響

第5章 市場變數與展望

  • SWOT分析
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 社會形勢
    • 技術形勢
    • 環境形勢
    • 法律上的形勢
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商的威脅
    • 競爭企業間的敵對關係
  • 熱圖分析

第6章 全球缺血性中風市場:各診斷(2019年～2032年(100萬美元))

  • 頸動脈超音波
  • 大腦超音波
  • 複合血管造影術
  • 心臟超音波圖
  • 心電圖
  • 磁振造影
  • 其他

第7章 全球缺血性中風市場:各藥物類別(2019年～2032年(100萬美元))

  • 組織纖維蛋白溶酶原活化劑
  • 抗凝固劑
  • 抗血小板劑
  • 降壓劑
  • 其他

第8章 全球缺血性中風市場:各手術(2019年～2032年(100萬美元))

  • 血管成形術
  • 頸動脈內薄膜剝離術
  • 血管內機械性血栓消除術

第9章 全球缺血性中風市場:各終端用戶(2019年～2032年(100萬美元))

  • 醫院、診所
  • 醫療機關
  • 研究機關
  • 其他

第10章 全球缺血性中風市場:各地區(2019年～2032年(100萬美元))

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他的亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中東、非洲
    • 沙烏地阿拉伯王國
    • 阿拉伯聯合大公國
    • 其他的中東、非洲

第11章 企業簡介

  • Abott Laboratories
    • 企業概要
    • 財務展望
    • 產品概要
    • 最近的開發
  • Bayer AG
  • Boehringer Ingelheim
  • Boston Scientific Corporation
  • Cordis Corporation
  • Covidien plc
  • GE Healthcare
  • Genentech, Inc.
  • Jhonson & Jhonson
  • Koninklijke Philips N.V.
  • Medtronic plc
  • Merck & Co. Inc.
  • Philips Healthcare
  • Sanofi
  • Stryker Corporation
簡介目錄
Product Code: HLCA2231

Global Ischemic Stroke Market Overview:

According to SPER Market Research, the Global Ischemic Stroke Market is estimated to reach USD 13.54 billion by 2032 with a CAGR of 4.24%.

Strokes can also happen when the blood supply to the brain is cut off. Strokes frequently happen when a blood vessel in the brain rupture, allowing haemorrhage to escape. This fracture, or any other sort of obstruction, prevented the blood and oxygen from reaching the brain tissues. Transient ischemic attack (TIA), haemorrhagic stroke, or ischemic stroke are the three main types of strokes that affect everyone in the globe. This procedure uses popular diagnostic tools like echocardiograms, MRIs, CT scans, cerebral angiograms, and blood tests. Treatments for this condition include aspirin, other antiplatelet medications, and anticoagulants.The market for ischemic stroke is being driven by factors such increased health awareness, rising diabetes rates, a rise in tobacco use, and an ageing population. However, the development of new developing technologies for ischemic stroke detection and treatment methods also contributes to the market growth. The maximum amount of blood typically stops abruptly reaching certain parts of the brain, which is how an ischemic stroke usually happens. The region and mechanism of ischemic strokes can be separated. Depending on how they grow within the bodily components, all blood clots inside the body are either thrombotic or embolic.There are expected to be significant growth opportunities in the market for acute ischemic stroke diagnosis and treatment as a result of increased public awareness of stroke and the range of market-available treatments, encouraging government initiatives, and the quickening pace of technological advancements in surgical procedures.The market for the diagnosis and treatment of acute ischemic stroke is expected to grow, but this is expected to be constrained by the high cost of care and the unfavourable reimbursement environment. Additionally, there may be challenges due to the numerous issues associated with product development and manufacturing.

Impact of COVID-19 on the Global Ischemic Stroke Market

According to the Ischemic Stroke market analysis, the virus known as the severity of acute respiratory syndrome of coronavirus 2 that is spread within people is the cause of this condition. Additionally, there has been a slight decline in hospital sectors as a result of the COVID-19 pandemic. It was as a result of individuals becoming afraid of the infection during the lockdown and distance-keeping phase. For health emergencies, a number of nations imposed a rigorous lockdown on their territory. The international trade and business sectors have been suspended for a while. The need for cutting-edge medical equipment has already increased during the lockdown.The COVID-19 has had a direct impact on the global hospital and healthcare industries. Overall, the disease had a very seriously detrimental effect on the market value for ischemic strokes. Investors have suffered a significant loss as a result of the decline in production and manufacturing work. Furthermore, because of several hospital-based therapies for ischemic stroke patients, the major companies in this business are obligated to cut their investment in raw materials and resources. It is also one of the most crucial things to go through at this difficult time. Since every worldwide industry has been severely impacted by this epidemic, most manufacturers aim to satisfy the needs of many industries.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Diagnosis, By Drug Class, By Surgery, By End User

Regions covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Abott Laboratories, Bayer AG, Boehringer Ingelheim, Boston Scientific Corporation, Cordis Corporation, Covidien plc, GE Healthcare, Genentech, Inc., Jhonson & Jhonson, Koninklijke Philips N.V., Medtronic plc, Merck & Co., Inc., Philips Healthcare, Sanofi, Stryker Corporation

Global Ischemic Stroke Market Segmentation:

By Diagnosis: Based on the Diagnosis, Global Ischemic Stroke Market is segmented as; Carotid Ultrasound, Cerebral Angiography, Computed Tomography, Echocardiography, Electrocardiography, Magnetic Resonance Imaging, Others.

By Drug Class: Based on the Drug Class, Global Ischemic Stroke Market is segmented as; Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, Antihypertensive, Others.

By Surgery: Based on the Surgery, Global Ischemic Stroke Market is segmented as; Angioplasty, Carotid Endarterectomy, Endovascular Mechanical Thrombectomy.

By End User: Based on the End User, Global Ischemic StrokeMarket is segmented as; Hospitals & Clinic, Medical Institutes, Research Organization, Others.

By Region: Due to rapid technological improvement in the acute ischemic stroke treatment process and supportive government policies, the North American area dominates the acute ischemic stroke diagnosis and treatment market. Because of the rise in ischemic stroke Asia-Pacific is anticipated to develop much faster than the global average.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Ischemic Stroke Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Ischemic Stroke Market, By Diagnosis, 2019-2032 (USD Million)

  • 6.1. Carotid Ultrasound
  • 6.2. Cerebral Ultrasound
  • 6.3. Compound Angiography
  • 6.4. Echocardiography
  • 6.5. Electrocardiography
  • 6.6. Magnetic Resonance Imaging
  • 6.7. Others

7. Global Ischemic Stroke Market, By Drug Class, 2019-2032 (USD Million)

  • 7.1. Tissue Plasminogen Activator
  • 7.2. Anticoagulant
  • 7.3. Antiplatelet
  • 7.4. Antihypertensive
  • 7.5. Others

8. Global Ischemic Stroke Market, By Surgery, 2019-2032 (USD Million)

  • 8.1. Angioplasty
  • 8.2. Carotid Endarterectomy
  • 8.3. Endovascular Mechanical Thrombectomy

9. Global Ischemic Stroke Market, By End User, 2019-2032 (USD Million)

  • 9.1. Hospitals & Clinic
  • 9.2. Medical Institutes
  • 9.3. Research Organization
  • 9.4. Others

10. Global Ischemic Stroke Market, By Region, 2019-2032 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. Abott Laboratories
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. Bayer AG
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. Boehringer Ingelheim
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. Boston Scientific Corporation
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Cordis Corporation
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Covidien plc
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. GE Healthcare
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Genentech, Inc.
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. Jhonson&Jhonson
    • 11.9.1. Company details
    • 11.9.2. Financial outlook
    • 11.9.3. Product summary
    • 11.9.4. Recent developments
  • 11.10. Koninklijke Philips N.V.
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. Medtronic plc
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. Merck & Co. Inc.
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. Philips Healthcare
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Sanofi
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. Stryker Corporation
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments